Skip to main content

Outcomes of hypofractionated stereotactic radiotherapy for metastatic brain tumors with high risk factors

Journal of Neuro-Oncology volume 109, pages 425–432 (2012)Cite this article

Abstract

The present study aimed to analyze outcomes of hypofractionated stereotactic radiotherapy (HFSRT) delivered in five fractions to metastatic brain tumors. Between June 2008 and June 2011, 39 consecutive patients with 46 brain metastases underwent HFSRT at Kyoto University Hospital. Selection criteria included high risk factors such as eloquent location, history of whole-brain radiotherapy (WBRT), or large tumor size. Given these factors, fractionated schedules were preferable in terms of radiobiology. The prescribed dose at the isocenter was basically 35 Gy in five fractions. Brainstem lesions with a history of WBRT were treated with 20–25 Gy in five fractions. Planning target volume was covered by the 80 % isodose line of the prescribed dose to the isocenter. Local-control probability and overall survival were estimated using the Kaplan–Meier method. For the analysis of local control, the response criteria were defined as follows: complete response (CR) was defined as no visible gross tumor or absence of contrast enhancement, partial response (PR) as more than a 30 % decrease in size, progressive disease as more than a 20 % increase in size, and stable disease (SD) as all other responses. Local control was defined as a status of CR, PR, or SD. Only patients with at least 3 months or longer follow-up (21 patients, 27 tumors) were included in the analysis. Median age and Karnofsky performance status were 59 years (range, 39–84 years) and 90 (range, 40–100), respectively. Tumor volumes and maximum diameters ranged from 0.08 to 15.38 cm3 (median, 3.67 cm3) and from 3 to 34 mm (median, 18 mm), respectively. The median follow-up period was 329 days (range, 120–1,321 days). Local-control probabilities at 6 and 12 months were 92.1 and 86.7 %, respectively. Overall survival after HFSRT at 6 and 12 months was 85.4 and 64.5 %, respectively. Grade 3 radiation necrosis was observed in one patient according to the Common Terminology Criteria for Adverse Events version 3.0. The patient was successfully managed conservatively. HFSRT for metastatic brain tumors yields high local-control probabilities without increasing severe adverse events despite high risk factors.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Soffietti R, Ruda R, Trevisan E (2008) Brain metastases: current management and new developments. Curr Opin Oncol 20:676–684. doi:10.1097/CCO.0b013e32831186fe

    PubMed  Article  Google Scholar 

  2. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280:1485–1489

    PubMed  Article  CAS  Google Scholar 

  3. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500. doi:10.1056/NEJM199002223220802

    PubMed  Article  CAS  Google Scholar 

  4. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665–1672. doi:10.1016/S0140-6736(04)16250-8

    PubMed  Article  Google Scholar 

  5. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295:2483–2491. doi:10.1001/jama.295.21.2483

    PubMed  Article  CAS  Google Scholar 

  6. Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Collette S, Collette L, Mueller RP (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. J Clin Oncol 29:134–141. doi:10.1200/JCO.2010.30.1655

    PubMed  Article  Google Scholar 

  7. Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, Farnan N (2000) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90–05. Int J Radiat Oncol Biol Phys 47:291–298

    PubMed  Article  CAS  Google Scholar 

  8. Williams BJ, Suki D, Fox BD, Pelloski CE, Maldaun MV, Sawaya RE, Lang FF, Rao G (2009) Stereotactic radiosurgery for metastatic brain tumors: a comprehensive review of complications. J Neurosurg 111:439–448. doi:10.3171/2008.11.JNS08984

    PubMed  Article  Google Scholar 

  9. Brenner DJ, Martel MK, Hall EJ (1991) Fractionated regimens for stereotactic radiotherapy of recurrent tumors in the brain. Int J Radiat Oncol Biol Phys 21:819–824

    PubMed  Article  CAS  Google Scholar 

  10. Hall EJ, Brenner DJ (1993) The radiobiology of radiosurgery: rationale for different treatment regimes for AVMs and malignancies. Int J Radiat Oncol Biol Phys 25:381–385

    PubMed  Article  CAS  Google Scholar 

  11. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745–751

    PubMed  Article  CAS  Google Scholar 

  12. Takakura T, Mizowaki T, Nakata M, Yano S, Fujimoto T, Miyabe Y, Nakamura M, Hiraoka M (2010) The geometric accuracy of frameless stereotactic radiosurgery using a 6D robotic couch system. Phys Med Biol 55:1–10. doi:10.1088/0031-9155/55/1/001

    PubMed  Article  CAS  Google Scholar 

  13. Kelly PJ, Lin YB, Yu AY, Ropper AE, Nguyen PL, Marcus KJ, Hacker FL, Weiss SE (2011) Linear accelerator-based stereotactic radiosurgery for brainstem metastases: the Dana-Farber/Brigham and Women’s Cancer Center experience. J Neurooncol 104:553–557. doi:10.1007/s11060-010-0514-0

    PubMed  Article  Google Scholar 

  14. Linskey ME, Andrews DW, Asher AL, Burri SH, Kondziolka D, Robinson PD, Ammirati M, Cobbs CS, Gaspar LE, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Ryken TC, Kalkanis SN (2010) The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96:45–68. doi:10.1007/s11060-009-0073-4

    PubMed  Article  Google Scholar 

  15. Matsuo T, Shibata S, Yasunaga A, Iwanaga M, Mori K, Shimizu T, Hayashi N, Ochi M, Hayashi K (1999) Dose optimization and indication of Linac radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 45:931–939

    PubMed  Article  CAS  Google Scholar 

  16. Vogelbaum MA, Angelov L, Lee SY, Li L, Barnett GH, Suh JH (2006) Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin. J Neurosurg 104:907–912. doi:10.3171/jns.2006.104.6.907

    PubMed  Article  Google Scholar 

  17. Schomas DA, Roeske JC, MacDonald RL, Sweeney PJ, Mehta N, Mundt AJ (2005) Predictors of tumor control in patients treated with linac-based stereotactic radiosurgery for metastatic disease to the brain. Am J Clin Oncol 28:180–187

    PubMed  Article  Google Scholar 

  18. Molenaar R, Wiggenraad R, Verbeek-de Kanter A, Walchenbach R, Vecht C (2009) Relationship between volume, dose and local control in stereotactic radiosurgery of brain metastasis. Br J Neurosurg 23:170–178. doi:10.1080/02688690902755613

    PubMed  Article  Google Scholar 

  19. Chang EL, Hassenbusch SJ III, Shiu AS, Lang FF, Allen PK, Sawaya R, Maor MH (2003) The role of tumor size in the radiosurgical management of patients with ambiguous brain metastases. Neurosurgery 53:272–280, discussion 280–281

    PubMed  Article  Google Scholar 

  20. Shehata MK, Young B, Reid B, Patchell RA, St Clair W, Sims J, Sanders M, Meigooni A, Mohiuddin M, Regine WF (2004) Stereotatic radiosurgery of 468 brain metastases < or =2 cm: implications for SRS dose and whole brain radiation therapy. Int J Radiat Oncol Biol Phys 59:87–93. doi:10.1016/j.ijrobp.2003.10.009

    PubMed  Article  Google Scholar 

  21. Manning MA, Cardinale RM, Benedict SH, Kavanagh BD, Zwicker RD, Amir C, Broaddus WC (2000) Hypofractionated stereotactic radiotherapy as an alternative to radiosurgery for the treatment of patients with brain metastases. Int J Radiat Oncol Biol Phys 47:603–608

    PubMed  Article  CAS  Google Scholar 

  22. Ikushima H, Tokuuye K, Sumi M, Kagami Y, Murayama S, Ikeda H, Tanaka M, Oyama H, Shibui S, Nomura K (2000) Fractionated stereotactic radiotherapy of brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 48:1389–1393

    PubMed  Article  CAS  Google Scholar 

  23. Aoyama H, Shirato H, Onimaru R, Kagei K, Ikeda J, Ishii N, Sawamura Y, Miyasaka K (2003) Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull. Int J Radiat Oncol Biol Phys 56:793–800

    PubMed  Article  Google Scholar 

  24. Ernst-Stecken A, Ganslandt O, Lambrecht U, Sauer R, Grabenbauer G (2006) Phase II trial of hypofractionated stereotactic radiotherapy for brain metastases: results and toxicity. Radiother Oncol 81:18–24. doi:10.1016/j.radonc.2006.08.024

    PubMed  Article  Google Scholar 

  25. Narayana A, Chang J, Yenice K, Chan K, Lymberis S, Brennan C, Gutin PH (2007) Hypofractionated stereotactic radiotherapy using intensity-modulated radiotherapy in patients with one or two brain metastases. Stereotact Funct Neurosurg 85:82–87. doi:10.1159/000097923

    PubMed  Article  Google Scholar 

  26. Fahrig A, Ganslandt O, Lambrecht U, Grabenbauer G, Kleinert G, Sauer R, Hamm K (2007) Hypofractionated stereotactic radiotherapy for brain metastases—results from three different dose concepts. Strahlenther Onkol 183:625–630. doi:10.1007/s00066-007-1714-1

    PubMed  Article  Google Scholar 

  27. Kwon AK, Dibiase SJ, Wang B, Hughes SL, Milcarek B, Zhu Y (2009) Hypofractionated stereotactic radiotherapy for the treatment of brain metastases. Cancer 115:890–898. doi:10.1002/cncr.24082

    PubMed  Article  Google Scholar 

  28. Kim YJ, Cho KH, Kim JY, Lim YK, Min HS, Lee SH, Kim HJ, Gwak HS, Yoo H (2011) Single-dose versus fractionated stereotactic radiotherapy for brain metastases. Int J Radiat Oncol Biol Phys 81:483–489. doi:10.1016/j.ijrobp.2010.05.033

    PubMed  Article  Google Scholar 

  29. Wiggenraad R, Verbeek-de Kanter A, Kal HB, Taphoorn M, Vissers T, Struikmans H (2011) Dose-effect relation in stereotactic radiotherapy for brain metastases. A systematic review. Radiother Oncol 98:292–297. doi:10.1016/j.radonc.2011.01.011

    PubMed  Article  Google Scholar 

  30. Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, Delattre JY (2009) CNS complications of radiotherapy and chemotherapy. Lancet 374:1639–1651. doi:10.1016/S0140-6736(09)61299-X

    PubMed  Article  CAS  Google Scholar 

  31. Varlotto JM, Flickinger JC, Niranjan A, Bhatnagar AK, Kondziolka D, Lunsford LD (2003) Analysis of tumor control and toxicity in patients who have survived at least one year after radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 57:452–464

    PubMed  Article  Google Scholar 

Download references

Acknowledgment

This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (20229009).

Author information

Affiliations

  1. Department of Radiation Oncology and Image-Applied Therapy, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan

    Kengo Ogura, Takashi Mizowaki, Masakazu Ogura, Katsuyuki Sakanaka & Masahiro Hiraoka

  2. Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Yoshiki Arakawa & Susumu Miyamoto

Authors
  1. Kengo Ogura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takashi Mizowaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masakazu Ogura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katsuyuki Sakanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshiki Arakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Susumu Miyamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masahiro Hiraoka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takashi Mizowaki.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ogura, K., Mizowaki, T., Ogura, M. et al. Outcomes of hypofractionated stereotactic radiotherapy for metastatic brain tumors with high risk factors. J Neurooncol 109, 425–432 (2012). https://doi.org/10.1007/s11060-012-0912-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-012-0912-6

Keywords

  • Metastatic brain tumors
  • Hypofractionated
  • Stereotactic radiotherapy
  • Local control
  • Toxicity